CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma

Eleven patients with advanced progressive metastatic adrenal cortical carcinoma, for whom no further standard therapy was available, were entered into a phase II study of cyclophosphamide, doxorubicin, and cisplatin (CAP) combination chemotherapy. Two partial responses and six disease stabilizations were observed. Patients with partial responses survived 18+ and 23 months; the median survival of patients with disease stabilization was 10+ months. The total group had a median survival of 10+ months. These results, together with the modest toxicity, suggest that further study of the combination is warranted.